Source link : https://www.newshealth.biz/health-news/promising-phase-2-results-for-myasthenia-gravis-med/
TOPLINE: The monoclonal antibody nipocalimab improves scores related to activities of daily living in a dose-dependent manner, lowers relevant autoantibody levels, and has an acceptable safety and tolerability profile in patients with generalized myasthenia gravis (gMG), results of a phase 2 trial suggested. METHODOLOGY: The double-blind phase 2 study (Vivacity-MG) included 68 adults with gMG, […]
Author : News Health
Publish date : 2024-01-09 10:03:48
Copyright for syndicated content belongs to the linked Source.